Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373088 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL28933257 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL31758954 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL31373160 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL18858998 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL31373162 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL31373165 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL13434049 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL14211649 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN | |
| SCHEMBL26983859 | 1.00 | MGMT (0.43) | MGMTABCG2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034396-B2 | Bioadhesive composition formed using click chemistry | TYCO HEALTHCARE GROUP LP (US) | 2011-10-11 | — | — | US | claimed |
| EP-2106809-A2 | Bioadhesive composition formed using click chemistry | Tyco Healthcare Group LP (US) | 2009-10-07 | — | — | EP | claimed |
| US-20090247651-A1 | Bioadhesive Composition Formed Using Click Chemistry | TYCO HEALTHCARE GROUP LP | 2009-10-01 | — | — | US | claimed |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260027047-A1 | HYDROGELS FOR CELL THERAPY | ADOCIA (FR) | 2026-01-29 | — | — | US | disclosed |
| WO-2025226800-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4554983-A1 | HYDROGELS FOR CELL THERAPY | Adocia (FR) | 2025-05-21 | — | — | EP | disclosed |
| CN-119948065-A | Hydrogels for cell therapy | 阿道恰公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119855837-A | Hydrogels for cell therapy | 阿道恰公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025027065-A1 | NOVEL SELECTIVE ACKR2 MODULATORS | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024081372-A1 | PROCESSES FOR THE PREPARATION OF THE AGENT-LINKER CONJUGATE CL2A-SN-38 AND THE IMMUNOCONJUGATES SACITUZUMAB GOVITECAN AND LABETUZUMAB GOVETICAN | GILEAD SCIENCES, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-8034396-B2 | Bioadhesive composition formed using click chemistry | TYCO HEALTHCARE GROUP LP (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110117016-A1 | DIAGNOSTIC COMPOUNDS | SOLBAKKEN MAGNE | 2011-05-19 | — | — | US | disclosed |
| US-7875701-B2 | A radiopharmaceutical based on a clyclic oligopeptide containing a fluorine isotope and the triplet amino acid sequence of arginine-glycine-aspartic acid (RGD); angiogenesis inhibitors by binding to integrin receptors; imaging using tomography; anticariogenic , -tumor and - arthritic agents; cardiotonic | GE HEALTHCARE AS (NO) | 2011-01-25 | — | — | US | disclosed |
| US-20100022746-A1 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | GE HEALTHCARE AS (NO) | 2010-01-28 | — | — | US | disclosed |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | GE HEALTHCARE AS (NO) | 2010-01-21 | — | — | US | disclosed |
| EP-2106809-A2 | Bioadhesive composition formed using click chemistry | Tyco Healthcare Group LP (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090247651-A1 | Bioadhesive Composition Formed Using Click Chemistry | TYCO HEALTHCARE GROUP LP | 2009-10-01 | — | — | US | disclosed |
| EP-1791571-B1 | RADIOFLUORINATED PEPTIDES | GE HEALTHCARE AS (NO) | 2008-08-13 | — | — | EP | disclosed |
| US-20080095701-A1 | Diagnostic Compounds | SOLBAKKEN MAGNE | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027047-A1 | HYDROGELS FOR CELL THERAPY | IAPP, ITGA1, ITGB1 | MGMT 1493/4885ABCG2 4693/4885CRBN 2398/4885 |
| US-20080095701-A1 | Diagnostic Compounds | CA13, SLCO1B3, KLK3 | MGMT 1745/4885ABCG2 86/4885CRBN 2702/4885 |
| US-20100022746-A1 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | QRFPR, DNPEP, VIP | MGMT 139/4885ABCG2 3395/4885CRBN 985/4885 |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | KLK3, BPHL, BRDT | MGMT 435/4885ABCG2 720/4885CRBN 1233/4885 |
| US-20090247651-A1 | Bioadhesive Composition Formed Using Click Chemistry | EPCAM, ICAM1, CDH1 | MGMT 45/4885ABCG2 796/4885CRBN 2495/4885 |
| US-20110117016-A1 | DIAGNOSTIC COMPOUNDS | CA13, SLCO1B3, KLK3 | MGMT 1745/4885ABCG2 86/4885CRBN 2702/4885 |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | VIP, QRFPR, GRPR | MGMT 901/4885ABCG2 3862/4885CRBN 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.